HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 6, 2024-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the formation of a Scientific Advisory Board (SAB) with leading
Novel, dual-pathway antibody targeting IL-17A and BAFF is expected to enter Phase 2 development in systemic sclerosis in Q4 2024 and hidradenitis suppurativa in Q2 2025 HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 3, 2024-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology
HENDERSON, Nev. --(BUSINESS WIRE)--May 29, 2024-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor
Ended Q1 2024 with $89.8 million in cash and closed oversubscribed $112.5 million private placement in April 2024 from new and existing leading life sciences institutional investors Appointed Robert Lisicki as CEO and Kiran Nistala , M.B.B.S., Ph.D. as CMO On track to initiate Phase 2 studies
- Financing includes new and existing leading life sciences institutional investors - Strengthened balance sheet expected to fund operations through 2027 HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 18, 2024-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company
- Succeeds Founding CEO, Dr. Someit Sidhu, who will continue as a Board Director - Recognized as inspirational industry leader with exceptional R&D, commercial and global executive experience - Outstanding product development and commercialization track record across a number of leading I&I
Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan On track to initiate Phase 2 study evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosis (SSc) in 2H 2024 Appointment of CEO,
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 4, 2024-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 2, 2024-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate
Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio’s Clinical Development programs Executive Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024 HENDERSON, Nev. --(BUSINESS WIRE)--Jan.